Welcome to our dedicated page for Amicus Therapeutics news (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics stock.
Amicus Therapeutics, Inc. (symbol: FOLD) is a global biotechnology company that specializes in discovering, developing, and delivering high-quality medicines for individuals suffering from rare metabolic diseases. The company's central focus revolves around addressing lysosomal storage disorders, such as Fabry disease and Pompe disease, through its innovative platform technologies and medicines.
Amicus Therapeutics operates with a patient-centric approach, ensuring that the needs of those in the rare disease community are at the forefront of their scientific research, commercial activities, and clinical programs. The company is dedicated to creating significant impacts on the lives of patients and their caregivers, striving to provide advanced therapeutic solutions where none previously existed.
The company's product pipeline includes:
- Galafold® (migalastat): An oral chaperone therapy approved for the treatment of adults with Fabry disease who have amenable genetic variants. Galafold works by stabilizing the body’s own dysfunctional enzyme to clear the accumulated substrate.
- Pombiliti™ and Opfolda™: A novel, two-component therapy designed for the treatment of late-onset Pompe disease, showcasing Amicus's commitment to addressing the complexities of metabolic disorders.
- Rare Disease Gene Therapy Portfolio: A set of advanced gene therapies aimed at providing long-lasting solutions for various rare metabolic diseases.
Amicus Therapeutics is focused on expanding its pipeline with first-in-class or best-in-class treatments, underscoring its commitment to innovative medical solutions. Financially, the company maintains a strong position, actively pursuing strategic priorities to sustain growth and enhance shareholder value.
With a presence in 27 countries, Amicus Therapeutics leverages a global footprint to address unmet medical needs across diverse patient populations. The company continuously seeks opportunities to broaden its impact and foster collaborations that advance its mission.
Recent developments include regulatory approvals and strategic partnerships aiming to enhance the reach and effectiveness of their therapies. By building strong relationships with stakeholders, Amicus Therapeutics ensures a collaborative effort in combating rare diseases.
Overall, Amicus Therapeutics Inc. embodies a profound dedication to transforming the lives of those affected by rare diseases through innovative science, patient-focused care, and robust therapeutic development.
Amicus Therapeutics (Nasdaq: FOLD) announced that its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL, on June 11, 2024, at 4:00 p.m. E.T.
The live audio webcast of the presentation will be accessible via the investors section of the Amicus Therapeutics website. Amicus Therapeutics is a biotechnology firm focused on developing medicines for rare diseases, committed to advancing a pipeline of innovative treatments.
Amicus Therapeutics (Nasdaq: FOLD) announced that its two-component therapy, Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), has won the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product. This prestigious award celebrates outstanding advances in the discovery and development of innovative products that improve human health. Pombiliti + Opfolda is the first and only therapy for eligible adults with late-onset Pompe disease, a debilitating lysosomal disorder. The award underscores the dedication of Amicus Therapeutics and the broader Pompe community in addressing this rare disease. The Galien Foundation, responsible for these awards, is committed to fostering innovation in medical science.
Amicus Therapeutics reported a total revenue of $110.4M for 1Q 2024, showing a 28% increase year-over-year. They raised their full-year 2024 revenue growth guidance to 25%-30%. Galafold sales increased by 15%, with Pombiliti + Opfolda sales growing by 30%. Non-GAAP profitability is projected for 2024. The company aims to achieve double-digit Galafold revenue growth and launch Pombiliti + Opfolda successfully.
Amicus Therapeutics will participate in the Bank of America 2024 Health Care Conference in Las Vegas. The company aims to present its dedication to developing medicines for rare diseases. The event will feature a fireside chat with management on May 15, 2024, at 1:40 p.m. P.T.
Amicus Therapeutics (Nasdaq: FOLD) will announce its first-quarter 2024 financial results on May 9, 2024. A conference call and live webcast will be held to discuss the results. The company is a global biotechnology firm focused on developing medicines for rare diseases.
FAQ
What is the current stock price of Amicus Therapeutics (FOLD)?
What is the market cap of Amicus Therapeutics (FOLD)?
What does Amicus Therapeutics, Inc. specialize in?
What is Galafold?
What are Pombiliti and Opfolda?
What makes Amicus Therapeutics unique?
How large is the footprint of Amicus Therapeutics?
What is the company's approach to patient care?
What recent achievements has Amicus Therapeutics made?
What is included in Amicus Therapeutics' gene therapy portfolio?
How does Amicus Therapeutics ensure its financial health?
How can one report adverse reactions to Amicus Therapeutics' products?
